Uncategorized
QLT releases Q2 financial results
QLT has announced its second-quarter financial results, including research and development expenses of $4.1 million related to the company’s synthetic retinoid program.The decrease from last year’s research and development expenses of $4.4 million is due primarily to the company’s workforce reduction related to the completion of the QLT091001 phase 1b retreatment study in patients with Leber congenital amaurosis and retinitis pigmentosa, according to a company press release.